Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bicara Therapeutics Inc.BCAX · Entity 4673 | Chief Legal Officer | February 02, 2026 | February 04, 2026 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Chief Legal Officer | June 15, 2023 | June 20, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bicara Therapeutics Inc.
Report date February 02, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.76 · Expires 2036-02-02 | Direct | 90,000 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 90,000 · Balance 90,000 F1: The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date.
Viridian Therapeutics, Inc.\DE
Report date June 15, 2023 · Filed June 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,971 |
Ending reported balance
After 2023-06-16 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-06-15 · Exercise / conversion · Acquired 2,269 · Balance 32,240 Row 2 · 2023-06-15 · Sale · Disposed 2,269 · Balance 29,971 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2023-06-16 · Exercise / conversion · Acquired 27 · Balance 29,998 Row 4 · 2023-06-16 · Sale · Disposed 27 · Balance 29,971 F2: This transaction was executed pursuant to the Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.03 · Expires 2031-01-18 | Direct | 37,481 |
Reported balance
After 2023-06-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-06-15 · Exercise / conversion · Disposed 2,269 · Balance 37,481 F3: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.03 · Expires 2031-01-18 | Direct | 37,453 |
Reported balance
After 2023-06-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-06-16 · Exercise / conversion · Disposed 28 · Balance 37,453 F3: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: This transaction was executed pursuant to the Plan.
F3: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2022 Filed Dec 20, 2022 00:22 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 300 | $23.03 | $6,909.00 |
DisclosureSEC source: 0000899243-22-039056 · doc4.xml · nonDerivative · entry 1 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 01:56 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,656 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-22-038520 · doc4.xml · derivative · entry 6 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,244 Underlying: Common Stock · 15,656 shares Expires 2031-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 01:56 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 15,656 | $28.12 | $440,246.72 |
DisclosureSEC source: 0000899243-22-038520 · doc4.xml · nonDerivative · entry 4 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.33. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.33. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 01:56 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 15,656 | $23.03 | $360,557.68 |
DisclosureSEC source: 0000899243-22-038520 · doc4.xml · nonDerivative · entry 3 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 01:56 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 600 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-22-038520 · doc4.xml · derivative · entry 5 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,900 Underlying: Common Stock · 600 shares Expires 2031-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 01:56 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 600 | $28.05 | $16,830.00 |
DisclosureSEC source: 0000899243-22-038520 · doc4.xml · nonDerivative · entry 2 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.02 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.02 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 01:56 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 600 | $23.03 | $13,818.00 |
DisclosureSEC source: 0000899243-22-038520 · doc4.xml · nonDerivative · entry 1 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 23:45 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,125 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-22-036044 · doc4.xml · derivative · entry 3 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,875 Underlying: Common Stock · 8,125 shares Expires 2031-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested 25% on September 22, 2022 and the remainder vests in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 23:45 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 8,125 | $22.05 | $179,156.25 |
DisclosureSEC source: 0000899243-22-036044 · doc4.xml · nonDerivative · entry 2 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $21.04 to $22.845. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $21.04 to $22.845. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 23:45 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 8,125 | $14.00 | $113,750.00 |
DisclosureSEC source: 0000899243-22-036044 · doc4.xml · nonDerivative · entry 1 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 23:12 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $18.51 | $0.00 |
DisclosureSEC source: 0000899243-22-004666 · doc4.xml · derivative · entry 1 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: The option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.